A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Resistance to therapy is a significant issue for patients with metastatic breast cancer (MBC). Here the authors analyze total miRNA from serum samples of 386 MBC patients before treatment with a follow up of 31 months and define a four miRNA signature that predicts the therapeutic benefit of trastuz...

Full description

Bibliographic Details
Main Authors: Huiping Li, Jiang Liu, Jianing Chen, Huiyun Wang, Linbin Yang, Fei Chen, Siting Fan, Jing Wang, Bin Shao, Dong Yin, Musheng Zeng, Mengfeng Li, Jun Li, Fengxi Su, Qiang Liu, Herui Yao, Shicheng Su, Erwei Song
Format: Article
Language:English
Published: Nature Publishing Group 2018-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-03537-w

Internet

https://doi.org/10.1038/s41467-018-03537-w

Similar Items